Tags

Type your tag names separated by a space and hit enter

Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment.
Clin Infect Dis 2007; 44(5):749-54CI

Abstract

BACKGROUND

We evaluated the immunologic impact of highly active antiretroviral therapy in subjects who maintained human immunodeficiency virus type 1 (HIV-1) suppression through 6 years of receiving a lopinavir-ritonavir-based regimen.

METHODS

A total of 100 antiretroviral-naive subjects with any CD4+ T cell count initiated therapy with lopinavir-ritonavir, stavudine, and lamivudine. Sixty-three subjects who remained in the study for 6 years were assessed. Laboratory measurements included plasma HIV-1 RNA levels, multiparameter flow cytometry of immune cells, and markers of maturation and activation.

RESULTS

After 6 years, 62 of 63 subjects had plasma HIV-1 RNA levels <50 copies/mL. The mean increase in CD4+ T cell count was 528 cells/microL (P<.001), and 81% of subjects had CD4+ T cell counts >500 cells/microL, compared with 21% of subjects at baseline. The mean ratio of CD4+ T cell count to CD8+ T cell count increased from 0.38 at baseline to 0.96 at year 6 (P<.001). The percentage of subjects with cell counts below the lower limit of normal at year 6, compared with at baseline, was significantly decreased for total T cells, B cells, and natural killer cells. At year 6, the median CD4+ T cell activation level was 3.4%, and the median CD8+ T cell activation level was 5.8%.

CONCLUSIONS

The receipt of a lopinavir-ritonavir-based regimen resulted in ongoing immune reconstitution through 6 years of therapy in a cohort of HIV-1-infected, antiretroviral-naive subjects with suppressed HIV-1 RNA levels. Normalization of activation marker expression on CD4+ and CD8+ T cell subsets was demonstrated.

Authors+Show Affiliations

Dept. of Immunology/Microbiology, Rush University Medical Center, Chicago, IL 60612, USA. alanday@rush.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17278071

Citation

Landay, Alan, et al. "Evidence of Ongoing Immune Reconstitution in Subjects With Sustained Viral Suppression Following 6 Years of Lopinavir-ritonavir Treatment." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 44, no. 5, 2007, pp. 749-54.
Landay A, da Silva BA, King MS, et al. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis. 2007;44(5):749-54.
Landay, A., da Silva, B. A., King, M. S., Albrecht, M., Benson, C., Eron, J., ... Hanna, G. J. (2007). Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 44(5), pp. 749-54.
Landay A, et al. Evidence of Ongoing Immune Reconstitution in Subjects With Sustained Viral Suppression Following 6 Years of Lopinavir-ritonavir Treatment. Clin Infect Dis. 2007 Mar 1;44(5):749-54. PubMed PMID: 17278071.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. AU - Landay,Alan, AU - da Silva,Barbara A, AU - King,Martin S, AU - Albrecht,Mary, AU - Benson,Constance, AU - Eron,Joseph, AU - Glesby,Marshall, AU - Gulick,Roy, AU - Hicks,Charles, AU - Kessler,Harold, AU - Murphy,Robert, AU - Thompson,Melanie, AU - White,A Clinton,Jr AU - Wolfe,Peter, AU - McMillan,Florence I, AU - Hanna,George J, Y1 - 2007/01/25/ PY - 2006/07/20/received PY - 2006/11/07/accepted PY - 2007/2/6/pubmed PY - 2007/3/27/medline PY - 2007/2/6/entrez SP - 749 EP - 54 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin. Infect. Dis. VL - 44 IS - 5 N2 - BACKGROUND: We evaluated the immunologic impact of highly active antiretroviral therapy in subjects who maintained human immunodeficiency virus type 1 (HIV-1) suppression through 6 years of receiving a lopinavir-ritonavir-based regimen. METHODS: A total of 100 antiretroviral-naive subjects with any CD4+ T cell count initiated therapy with lopinavir-ritonavir, stavudine, and lamivudine. Sixty-three subjects who remained in the study for 6 years were assessed. Laboratory measurements included plasma HIV-1 RNA levels, multiparameter flow cytometry of immune cells, and markers of maturation and activation. RESULTS: After 6 years, 62 of 63 subjects had plasma HIV-1 RNA levels <50 copies/mL. The mean increase in CD4+ T cell count was 528 cells/microL (P<.001), and 81% of subjects had CD4+ T cell counts >500 cells/microL, compared with 21% of subjects at baseline. The mean ratio of CD4+ T cell count to CD8+ T cell count increased from 0.38 at baseline to 0.96 at year 6 (P<.001). The percentage of subjects with cell counts below the lower limit of normal at year 6, compared with at baseline, was significantly decreased for total T cells, B cells, and natural killer cells. At year 6, the median CD4+ T cell activation level was 3.4%, and the median CD8+ T cell activation level was 5.8%. CONCLUSIONS: The receipt of a lopinavir-ritonavir-based regimen resulted in ongoing immune reconstitution through 6 years of therapy in a cohort of HIV-1-infected, antiretroviral-naive subjects with suppressed HIV-1 RNA levels. Normalization of activation marker expression on CD4+ and CD8+ T cell subsets was demonstrated. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/17278071/Evidence_of_ongoing_immune_reconstitution_in_subjects_with_sustained_viral_suppression_following_6_years_of_lopinavir_ritonavir_treatment_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/511681 DB - PRIME DP - Unbound Medicine ER -